首页> 外文期刊>European review for medical and pharmacological sciences. >The efficacy observation of ulinastatin combined with creatine phosphate sodium in pediatric viral myocarditis
【24h】

The efficacy observation of ulinastatin combined with creatine phosphate sodium in pediatric viral myocarditis

机译:乌纳替肽与肌酸磷酸钠钠联合儿科病毒心肌炎的功效观察

获取原文
           

摘要

OBJECTIVE: This study aimed to compare the efficacy and safety of ulinastatin combined with creatine phosphate sodium and ribavirin combined with creatine phosphate sodium in the treatment of pediatric viral myocarditis. PATIENTS AND METHODS: 155 children with viral myocarditis in the Xuzhou Children’s Hospital, were retrospectively analyzed. 80 of them received ulinastatin combined with creatine phosphate sodium, and were regarded as observation group; other 75 patients received ribavirin combined with creatine phosphate sodium and were regarded as the control group. The therapeutic efficacy of the two groups was observed, the improved condition of myocardial enzyme indicator and myocardial troponin I (cTn I) in the two groups were compared before and after the treatment. RESULTS: The total effective rates of the patients in the observation group and the control group were 93.75% and 76.00%, respectively. The clinical efficacy of the observation group was better than that of the control group (p0.05). The electrocardiogram improvement condition of the observation group was better than that of the control group (p0.05); after the treatment, the expression levels of lactate dehydrogenase (LDH), aspartate aminotransferase (AST), Creatine Kinase (CK-MB), and cTn I in the observation group were (313.37±9.42) U/L, (29.38±4.97) U/L, (23.67±2.89) U/L, (0.12±0.02) μg/L, respectively. The expression levels of LDH, AST, CK-MB, and cTn I in the control group were (322.43±12.32) U/L, (33.43±5.14) U/L, (26.22±3.37) U/L, (0.24±0.04) μg/L. The levels of myocardial enzyme and cTn I in the observation group and the control group after the treatment were lower than that before the treatment (p0.05), while the level of myocardial enzyme and cTn I in the observation group after the treatment was significantly lower than that in the control group (p0.05). CONCLUSIONS: The results indicated that, compared with ribavirin combined with creatine phosphate sodium, ulinastatin combined with creatine phosphate sodium had better clinical efficacy in the treatment of pediatric viral myocarditis. It could significantly improve the level of myocardial enzyme indicator and cTn I, and had certain clinical and promotional values and application values.
机译:目的:本研究旨在比较乌凡司汀与肌酸磷酸盐钠和利巴韦林联合肌酸磷酸盐钠在治疗儿科病毒心肌炎中的疗效和安全性。患者和方法:徐州儿童医院有155名患有病毒心肌炎的儿童,回顾性分析。其中80个接受乌纳替肽与肌酸磷酸钠联合,并被视为观察组;其他75名患者接受利巴韦林联合肌酸磷酸钠钠,并被视为对照组。观察到两组的治疗效果,在治疗之前和之后比较了两组中心肌酶指示剂和心肌肌钙蛋白I(CTN I)的改善条件。结果:观察组和对照组患者的总有效率分别为93.75%和76.00%。观察组的临床疗效优于对照组(P <0.05)。观察组的心电图改善条件优于对照组(P <0.05);治疗后,观察组中乳酸脱氢酶(LDH),天冬氨酸氨基转移酶(AST),肌酸激酶(CK-MB)和CTN I的表达水平为(313.37±9.42)U / L(29.38±4.97) U / L,(23.67±2.89)U / L,(0.12±0.02)μg/ L.对照组中LDH,AST,CK-MB和CTN I的表达水平为(322.43±12.32)U / L,(33.43±5.14)U / L(26.22±3.37)U / L(0.24± 0.04)μg/升。治疗前观察组和对照组在观察组和对照组中的心肌酶和CTN i水平(P <0.05),而治疗后观察组的心肌酶和CTN I水平显着低于对照组(P <0.05)。结论:结果表明,与利巴韦林联合肌酸磷酸钠钠相比,乌氏菌素联合肌酸磷酸盐钠在治疗儿科病毒心肌炎中具有更好的临床疗效。它可以显着提高心肌酶指标和CTN I的水平,并具有某些临床和促销价值和应用值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号